ELAN in the 13F filings
Elanco Animal Health Inc · CUSIP 28414H103
- Quarter end
- 30 Sep 2025
- the date the book describes
- Filed
- 14 Nov 2025
- latest of these filings; the earliest 13 Nov 2025
- Managers listing it
- 12
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q2 2025 and Q3 2025; 8 listed it in both
- Shares listed
- 169,068,261
- combined, among listed positions
- Reported value
- $3.4bn
- combined, at the quarter end
Among the 95 comparable managers: 7 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing ELAN in Q3 2025
12 of 12 holders
Largest increases and reductions, by shares
Increases
- Woodline Partners LPexisting position · 3,669,503 shares now+480,318
- Fidelity (FMR LLC)existing position · 65,357,380 shares now+473,983
- ExodusPoint Capital Management LPnew position · 271,714 shares now+271,714
- Capital World Investorsexisting position · 2,078,888 shares now+78,888
- Winton Group Ltdnew position · 41,630 shares now+41,630
Reductions
- Holocene Advisors LPexisting position · 2,093,054 shares now-793,240
- Point72 Asset Management LPexisting position · 1,260,400 shares now-709,407
- Balyasny Asset Management LLCexisting position · 2,050,287 shares now-259,599
- Dodge & Coxexisting position · 82,759,837 shares now-135,395
- Freestone Grove Partners LPexisting position · 3,841,422 shares now-9,628
New positions and exits
New (3)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2018 | 13 | $388m | n.a. | n.a. |
| Q4 2018 | 7 | $383m | n.a. | n.a. |
| Q1 2019 | 14 | $3.5bn | n.a. | n.a. |
| Q2 2019 | 10 | $3.7bn | n.a. | n.a. |
| Q3 2019 | 13 | $2.9bn | n.a. | n.a. |
| Q4 2019 | 13 | $3.3bn | n.a. | n.a. |
| Q1 2020 | 13 | $2.9bn | n.a. | n.a. |
| Q2 2020 | 12 | $2.4bn | n.a. | n.a. |
| Q3 2020 | 6 | $2.9bn | n.a. | n.a. |
| Q4 2020 | 16 | $4.1bn | n.a. | n.a. |
| Q1 2021 | 12 | $4.0bn | n.a. | n.a. |
| Q2 2021 | 14 | $4.6bn | n.a. | n.a. |
| Q3 2021 | 10 | $4.0bn | n.a. | n.a. |
| Q4 2021 | 13 | $3.8bn | n.a. | n.a. |
| Q1 2022 | 11 | $3.1bn | n.a. | n.a. |
| Q2 2022 | 11 | $2.4bn | n.a. | n.a. |
| Q3 2022 | 15 | $1.9bn | n.a. | n.a. |
| Q4 2022 | 15 | $1.7bn | n.a. | n.a. |
| Q1 2023 | 12 | $1.2bn | n.a. | n.a. |
| Q2 2023 | 13 | $1.6bn | n.a. | n.a. |
| Q3 2023 | 12 | $1.7bn | n.a. | n.a. |
| Q4 2023 | 9 | $1.9bn | 2 | 9 |
| Q1 2024 | 10 | $2.3bn | 7 | 3 |
| Q2 2024 | 9 | $2.1bn | 6 | 4 |
| Q3 2024 | 7 | $1.5bn | 4 | 3 |
| Q4 2024 | 5 | $1.5bn | 2 | 2 |
| Q1 2025 | 6 | $1.5bn | 4 | 1 |
| Q2 2025 | 9 | $2.5bn | 8 | 2 |
| Q3 2025 | 12 | $3.4bn | 7 | 5 |
| Q4 2025 | 9 | $3.3bn | 17 | 15 |
| Q1 2026 | 5 | $3.0bn | 15 | 16 |
| Q2 2026 | 10 | $3.6bn | 15 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ELAN and LLY →ELAN and JNJ →ELAN and VRTX →Choose a stock to compare with ELAN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ELAN, latest filings →Back to the 13F Explorer →